allicin has been researched along with angiotensin ii in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hu, JJ; Jia, W; Li, CY; Li, XH; Lu, JM; Tian, RB; Xiang, ZG | 1 |
| Ba, L; Cao, Y; Chen, Y; Dong, C; Gao, J; Guan, X; Pan, H; Qi, H; Shi, P; Song, C; Sun, H; Zhang, Q | 1 |
2 other study(ies) available for allicin and angiotensin ii
| Article | Year |
|---|---|
Allicin ameliorates cardiac hypertrophy and fibrosis through enhancing of Nrf2 antioxidant signaling pathways.
Topics: Angiotensin II; Animals; Antioxidants; Collagen; Disulfides; Fibrosis; Glutamate-Cysteine Ligase; Hemodynamics; Hypertrophy, Left Ventricular; Male; NF-E2-Related Factor 2; Organ Size; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; RNA, Messenger; Signal Transduction; Sulfinic Acids | 2012 |
Allicin attenuates pathological cardiac hypertrophy by inhibiting autophagy via activation of PI3K/Akt/mTOR and MAPK/ERK/mTOR signaling pathways.
Topics: Angiotensin II; Animals; Autophagy; Cardiomegaly; Cardiotonic Agents; Disulfides; Male; MAP Kinase Signaling System; Myocytes, Cardiac; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats, Wistar; Signal Transduction; Sulfinic Acids; TOR Serine-Threonine Kinases | 2019 |